The study is to determine whether MuPharma’s proprietary ultrasonic delivery device can deliver Avastin antibody to the subsclera tissue layers of the eye. The study will measure where the antibody migrates to within the eye substructures over 3 hours, with a focus on whether the antibody reaches the retina. The imaging is limited to studying both eyes and the head region of each rabbit.
|Short title||MuPharma Avastin proof of principle|
|Effective start/end date||1/06/19 → 1/01/20|
- MuPharma: A$16,904.00
Gary Egan (Manager) & Kylie Reid (Manager)Office of the Vice-Provost (Research and Research Infrastructure)
Camilla Cohen (Manager)Faculty of Medicine Nursing and Health Sciences Research Platforms